StockStory flags Align Technology growth and profit concerns

StockStory analysts advise caution regarding Align Technology (ALGN), citing a five-year compounded annual revenue growth rate of 3.6% that falls short of the firm's healthcare sector benchmark. This performance metric is central to their assessment of the company's long-term quality, distinguishing it from peers that consistently expand over longer horizons.

The firm’s analysis highlights a divergence between revenue expansion and profitability. While sales grew at a 3.6% compounded annual rate over the last five years, earnings per share increased at a slower 1.4% compounded annual rate. StockStory notes this dynamic indicates the company became less profitable on a per-share basis as it expanded, a key factor in their cautious stance despite the stock's recent price decline.

Further scrutiny is applied to Align Technology’s return on invested capital, or ROIC. The source reports that ROIC has decreased over the last few years, which StockStory interprets as a potential symptom of fewer profitable growth opportunities. Although the firm acknowledges past management success, the declining returns weigh on their investment thesis.

Currently trading at $144.11, Align Technology shares have experienced a 13.6% loss over the past six months, underperforming the S&P 500’s 17.5% gain over the same period. While StockStory characterizes this valuation as reasonable, they do not identify a significant opportunity at current levels and suggest investors consider alternative software businesses instead.